Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus

Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus - Effects of metformin and pioglitazone on pentosidine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002099

Enrollment

Registered

2009-06-21

Start date

2007-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes mellitus

Interventions

treatment with metformin treatment with pioglitazone treatment of sulfonylurea or insulin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes mellitus

Exclusion criteria

Exclusion criteria: Nobody had hepatic or renal dysfunction or nutritional derangements. Patients who had taken metformin or pioglitazone in the past were excluded from this study.

Design outcomes

Primary

Measure	Time frame
the effects of metformin or pioglitazone on serum pentosidine levels	—

Countries

Japan

Contacts

Public ContactIppei Kanazawa

Shimane University Faculty of Medicine Internal Medicine 1

ippei.k@med.shimane-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026